| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Review of promising Myostatin and Activin E antibody data
iBio to announce 3rd target in Astral Bio Collaboration
Conference call Tuesday, June 24 at 8:30 a.m. ET
iBio, Inc. (NASDAQ:IBIO), an AI-driven innovator of precision antibody therapies, today announced the Company will host a conference call on Tuesday, June 24, at 8:30 a.m. ET to review its latest advances in obesity and cardiometabolic disease treatments and announce a third target in the AstralBio Collaboration in addition to Myostatin and Activin E.
Martin Brenner, DVM, Ph.D., iBio's CEO and Chief Scientific Officer, will outline how iBio is pioneering the next generation of antibody medicines—targeted, longer-lasting, and potentially better tolerated therapies with more sustainable efficacy. Dr. Brenner will present a strategic overview of the obesity strategy, including details on their long acting Myostatin, IBIO-600, new preclinical data on Activin E and, more safe and effective treatment options.
The webcast of the live call may be accessed on the Investors section of the iBio website at ir.ibioinc.com/news-events/ir-calendar. A replay of the webcast will be available on the iBio website for approximately 60 days following the presentation.
Posted In: IBIO
